Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Recurrent Glioblastoma Multiforme
Interventions: 131-I-chTNT-1/B MAB; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Caregivers of Alzheimer's Disease or Memory Problem Patients
Interventions: Caregiving condition, Nutrition condition; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dyskeratosis Congenita, Aplastic Anemia
Interventions: Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Degenerative Disc Disease
Interventions: One-level or two-level anterior lumbar interbody fusion, InQu Bone Graft Extender and Substitute mixed with BMAC, Synthes Spinal Instrumentation; Procedure · Biological · Device
Lead sponsor: Kansas Joint and Spine Institute; Network
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Dry Eye Syndromes
Interventions: SJP-0035 0.001%, Placebo; Drug
Lead sponsor: Senju Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 23
States / cities: Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more

Conditions: Obstructive Sleep Apnea, Daytime Sleepiness
Interventions: Whole Food Plant-Based Diet; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer (Post Prostatectomy)
Interventions: 18F-rhPSMA-7.3 (Posluma); Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Acute Spinal Cord Injury
Interventions: GlyBURIDE Oral Tablet; Drug
Lead sponsor: Francis Farhadi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: BI 10773, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Plantation, Florida + 15 more

Conditions: Presbyopia
Interventions: Mitomycin c, Raindrop Near Vision Inlay; Drug · Device
Lead sponsor: Key-Whitman Eye Center; Other
Eligibility: 41 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Bloomington, Minnesota • Dallas, Texas • San Antonio, Texas

Conditions: Adenocarcinoma of the Ovary
Interventions: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine; Biological
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 3
States / cities: Zion, Illinois • Tulsa, Oklahoma • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Supportive Care (home-based physical activity), Exercise Intervention, telephone interview, Remote Monitoring, Patient Monitoring, Questionnaire Administration, Electronic Health Record Review; Behavioral · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Solid Tumors
Interventions: Oral ONC201; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chronic Lymphocytic Leukemia
Interventions: Sonrotoclax, Zanubrutinib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Weston, Florida • Marietta, Georgia • Niles, Illinois + 6 more

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions: 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline; Diagnostic Test · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Otorhinolaryngology Subjects Undergoing Free Flap Surgery
Interventions: Survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Tumor Sample, Serum Sample; Procedure
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Joint Arthrodesis, Joint Fixation
Interventions: SpeedPlate™ Rapid Compression Implants; Device
Lead sponsor: Treace Medical Concepts, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Decatur, Alabama • Orlando, Florida • Jefferson City, Missouri + 2 more

Conditions: Smoking Cessation
Interventions: Smoking Cessation Counseling; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Bladder Cancer
Interventions: Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Melanoma
Interventions: Vemurafenib, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 47
States / cities: Birmingham, Alabama • California City, California • Hayward, California + 38 more

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more

Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions: Cositecan, Pharmacological Study; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Caring for the Caregiver Network

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Spinal Cord Injury Neuroprotection With Glyburide

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

Oral ONC201 in Treating Patients With Advanced Solid Tumors

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Functional Outcome Measures for Head and Neck Patients

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

The SpeedPlate™ Rapid Compression Implant Study (The SPRINT™ Study)

Smoking Cessation Study

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge